Form 4: SCYNEXIS Director Armando Anido Receives Equity Grant Under Compensation Plan

SCYNEXIS Inc. Director Armando Anido is set to acquire 23,000 shares of common stock and 23,000 stock options on June 26, 2025, as part of an equity compensation plan.

Summary

• Armando Anido, a Director of SCYNEXIS INC (SCYX), is scheduled to acquire 23,000 shares of common stock and 23,000 stock options on June 26, 2025.
• The 23,000 shares of common stock were acquired at a price of $0, indicating they are likely a grant of restricted stock units (RSUs).
• The 23,000 stock options have an exercise price of $0.74 per share and an expiration date of June 25, 2035.
• Both the common stock (RSUs) and stock options are subject to a vesting schedule, with 100% vesting on the first anniversary of the grant date (June 26, 2025), provided continuous service as a non-employee director.
• Following these transactions, Armando Anido will beneficially own 71,000 shares of common stock and 23,000 stock options directly.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading instruction.

Sentiment

Score: 7

Explanation: The filing indicates a standard equity grant to a director, aligning their interests with shareholders and reflecting a routine compensation practice. There are no negative disclosures or unexpected events.

Positives

• Director Armando Anido's acquisition of additional equity aligns his interests with shareholders, demonstrating confidence in SCYNEXIS's future performance.
• The grant of restricted stock units and stock options is a common and effective form of non-employee director compensation, incentivizing long-term commitment and retention of experienced board members.

Risks

• The vesting of the granted shares and options is contingent on continuous service, meaning the director must remain with the company for the specified period to fully realize the value of the award.
• The ultimate value of the stock options and restricted stock units is subject to the future performance of SCYNEXIS's stock price, introducing market risk.

Future Outlook

The vesting schedule indicates a future commitment from the director, with 100% of the granted shares and options vesting on the first anniversary of the grant date (June 26, 2025), contingent on continuous service to the company.

Industry Context

Equity grants to non-employee directors are a standard practice in the biotechnology and pharmaceutical industry, where SCYNEXIS operates. This compensation method is widely used to align director interests with long-term shareholder value and to attract and retain experienced board members in a highly competitive sector.

Comparison to Industry Standards

• The grant of equity, including restricted stock units and stock options, to non-employee directors is a common compensation practice across the biotechnology and pharmaceutical sectors, comparable to how companies like Gilead Sciences, Amgen, or Biogen compensate their board members.
• The vesting schedule of one year for 100% of the grant is a typical structure for director equity awards, designed to ensure continued service and align with the company's long-term performance objectives.

Corporate Governance

Related Party Transactions

• Grant of 23,000 shares of common stock and 23,000 stock options to Director Armando Anido, which is a standard compensation transaction between the company and a related party (director).

Stakeholder Impact

• Shareholders: The equity grant aligns the director's interests with shareholders, potentially fostering long-term value creation and demonstrating confidence from the board.
• Employees: No direct impact on employees is mentioned in this filing.
• Customers: No direct impact on customers is mentioned in this filing.
• Suppliers: No direct impact on suppliers is mentioned in this filing.
• Creditors: No direct impact on creditors is mentioned in this filing.

Next Steps

• The granted shares and options are scheduled to vest on the first anniversary of the grant date, June 26, 2025, contingent on the director's continuous service.

Key Dates

Recommendation

Keywords

SCYNEXIS, SCYX, Form 4, Insider Transaction, Director Compensation, Equity Grant, Stock Options, Restricted Stock Units, Armando Anido, Corporate Governance, 10b5-1 Plan